N2 modified cap analogues as translation inhibitors and substrates for preparation of therapeutic mRNA

[1]  A. Kore,et al.  Recent Advances in Modified Cap Analogs: Synthesis, Biochemical Properties, and mRNA Based Vaccines , 2022, Chemical record.

[2]  J. Trylska,et al.  Insight into the Binding and Hydrolytic Preferences of hNudt16 Based on Nucleotide Diphosphate Substrates , 2021, International journal of molecular sciences.

[3]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[4]  P. Dormitzer,et al.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[5]  U. Qazi,et al.  COVID-19 Vaccine , 2020, Advances in Infectious Diseases.

[6]  Karol Kamel,et al.  Isoxazole-containing 5' mRNA cap analogues as inhibitors of the translation initiation process. , 2020, Bioorganic chemistry.

[7]  Z. Darżynkiewicz,et al.  Kinetic analysis of IFIT1 and IFIT5 interactions with different native and engineered RNAs and its consequences for designing mRNA-based therapeutics , 2019, RNA.

[8]  V. Cowling,et al.  mRNA cap regulation in mammalian cell function and fate , 2019, Biochimica et biophysica acta. Gene regulatory mechanisms.

[9]  A. Niedzwiecka,et al.  Modified ARCA analogs providing enhanced translational properties of capped mRNAs , 2018, Cell cycle.

[10]  Haopeng Sun,et al.  The recent progress of isoxazole in medicinal chemistry. , 2018, Bioorganic & medicinal chemistry.

[11]  J. Stȩpiński,et al.  Hydrolytic activity of human Nudt16 enzyme on dinucleotide cap analogs and short capped oligonucleotides , 2018, RNA.

[12]  D. Weissman.  mRNA transcript therapy , 2015, Expert review of vaccines.

[13]  M. Jankowska-Anyszka,et al.  Triazole-containing monophosphate mRNA cap analogs as effective translation inhibitors , 2014, RNA.

[14]  Özlem Türeci,et al.  mRNA-based therapeutics — developing a new class of drugs , 2014, Nature Reviews Drug Discovery.

[15]  T. Schlake,et al.  Developing mRNA-vaccine technologies , 2012, RNA biology.

[16]  M. Jankowska-Anyszka,et al.  Synthesis of N²-modified 7-methylguanosine 5'-monophosphates as nematode translation inhibitors. , 2012, Bioorganic & medicinal chemistry.

[17]  J. Kieft,et al.  Structural basis for nematode eIF4E binding an m2,2,7G-Cap and its implications for translation initiation , 2011, Nucleic acids research.

[18]  Jason E Hein,et al.  Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and beyond: new reactivity of copper(I) acetylides. , 2010, Chemical Society reviews.

[19]  E. Darżynkiewicz,et al.  Phosphorothioate analogs of m7GTP are enzymatically stable inhibitors of cap-dependent translation. , 2009, Bioorganic & medicinal chemistry letters.

[20]  Giovanni Sorba,et al.  Click chemistry reactions in medicinal chemistry: Applications of the 1,3‐dipolar cycloaddition between azides and alkynes , 2008, Medicinal research reviews.

[21]  Adam Bagg,et al.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.

[22]  R. Rhoads,et al.  Quantitative assessment of mRNA cap analogues as inhibitors of in vitro translation. , 1999, Biochemistry.

[23]  A. Pasquinelli,et al.  Reverse 5' caps in RNAs made in vitro by phage RNA polymerases. , 1995, RNA.

[24]  N. Sonenberg,et al.  Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap , 1990, Nature.

[25]  By Yasuhiro,et al.  Discovery of m 7 Gcap in eukaryotic mRNAs , 2015 .

[26]  R. Rhoads,et al.  Synthesis of anti-reverse cap analogs (ARCAs) and their applications in mRNA translation and stability. , 2007, Methods in enzymology.